The Clinical Added Value of Breast Cancer Imaging Using Hybrid PET/MR Imaging.

Dedicated MR imaging is highly performant for the evaluation of the primary lesion and should regularly be added to whole-body PET/MR imaging for the initial staging. PET/MR imaging is highly sensitive for the detection of nodal involvement and could be combined with the high specificity of axillary second look ultrasound for the confirmation of the N staging. For M staging, with the exception of lung lesions, PET/MR imaging is superior to PET/computed tomography, at half the radiation dose. The predictive value of multiparametric imaging with PET/MR imaging holds promise to improve through radiomics and artificial intelligence.

[68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [68Ga]Ga-PSMA-11. Herein, we summarize the preclinical development and the clinical applications of [68Ga]Ga-PSMA-11 and present side-by-side comparisons with other radiopharmaceuticals or imaging modalities, in order to assist imagers and clinicians in recommending, performing, and interpreting the results of [68Ga]Ga-PSMA-11 PET scans in patients with prostate cancer.

Dopaminergic imaging separates normal pressure hydrocephalus from its mimics.

OBJECTIVE: Idiopathic normal pressure hydrocephalus (iNPH) and iNPH mimics (i.e., Parkinson's disease, progressive supranuclear palsy or dementia with Lewy bodies) share similar clinical features, and discrimination between both conditions relies on invasive time-consuming investigations. This study aims to compare [123I]FP-CIT SPECT imaging-visual rating and semiquantitative values-between iNPH and iNPH mimics. METHODS: Among 56 patients with a suspicion of iNPH (76.5 ± 6.1 years; 23.2% women), 26 fulfilled the iNPH diagnostic criteria and the remaining 30 were classified as iNPH mimics. Patients were visually categorized as having normal or abnormal [123I]FP-CIT SPECT; and for the quantification of the [123I]FP-CIT SPECT imaging, we calculated striatal binding ratios (SBR) using BRASS™ automated brain analysis while applying locally established reference limits (adjusted for age). Logistic regressions were used to assess the association between [123I]FP-CIT SPECT and diagnostic groups. RESULTS: A normal SBR [123I]FP-CIT SPECT was present in 69.2% of iNPH and 37.9% of mimics (p value = .020), while visual rating did not differ between the two groups. Normal SBR [123I]FP-CIT SPECT values were associated with the diagnosis of iNPH, even after adjusting for white matter changes and comorbidities (adjusted odds ratio: 4.17; 95% CI 1.26-13.80). CONCLUSION: Semi-quantitative [123I]FP-CIT SPECT evaluation, but not visual assessment, discriminates iNPH patients from their mimics. [123I]FP-CIT SPECT represents an interesting neuroimaging biomarker to improve the selection of patients with iNPH for invasive shunt surgery.

Education-Adjusted Normality Thresholds for FDG-PET in the Diagnosis of Alzheimer Disease.

BACKGROUND: A corollary of the reserve hypothesis is that what is regarded as pathological cortical metabolism in patients might vary according to education. OBJECTIVE: The aim of this study is to assess the incremental diagnostic value of education-adjusted over unadjusted thresholds on the diagnostic accuracy of FDG-PET as a biomarker for Alzheimer disease (AD). METHODS: We compared cortical metabolism in 90 healthy controls and 181 AD patients from the Alzheimer Disease Neuroimaging Initiative (ADNI) database. The AUC of the ROC curve did not differ significantly between the whole group and the higher-education patients or the lower-education subjects. RESULTS: The threshold of wMetaROI values providing 80% sensitivity was lower in higher-education patients and higher in the lower-education patients, compared to the standard threshold derived over the whole AD collective, without, however, significant changes in sensitivity and specificity. CONCLUSION: These data show that education, as a proxy of reserve, is not a major confounder in the diagnostic accuracy of FDG-PET in AD and the adoption of education-adjusted thresholds is not required in daily practice.

The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study.

PURPOSE: Tumor hypoxia is associated with radioresistance and poor prognosis after radiation therapy for prostate cancer (PCa). In this prospective pilot study, we assessed the ability of 18F-misonidazole (18F-MISO) positron emission tomography (PET)-magnetic resonance imaging (MRI) to detect hypoxia in high-grade PCa patients who were candidates for curative radiation therapy, and we evaluated 18F-MISO PET-MRI modulation after 3 months of neoadjuvant androgen deprivation therapy (nADT). METHODS AND MATERIALS: Eleven PCa patients with a Gleason score (GS) ≥ 8 underwent 18F-fluorocholine (18F-FCH) PET-computed tomography at diagnosis and an 18F-MISO hybrid PET-MRI examination before nADT; a second 18F-MISO PET-MRI examination was acquired after 3 months of nADT for all patients but one who dropped out because of noncompliance with nADT. Immunohistochemistry for tissue hypoxia- and proliferation-related biomarkers (glucose transporter 1, carbonic anhydrase IX, vascular endothelial growth factor A, Ki-67, hypoxia-inducible factor 1 alpha, and epidermal growth factor receptor) was performed in lesions bearing the highest GS. We used nonparametric tests to assess (1) the presence of 18F-MISO-positive regions (tumor-to-background ratio [TBR] ≥ 1.4) at baseline; (2) the correlation between imaging parameters (PET tracer uptake, Prostate Imaging Reporting and Data System [PIRADS] scores, and dynamic contrast enhancement perfusion markers) at baseline; (3) the difference in immunohistochemistry staining between 18F-MISO-positive and -negative lesions; and (4) the changes in 18F-MISO PET-MRI after nADT. RESULTS: Uptake of 18F-MISO was significant in 7 patients, being coincidental with the highest GS region in 5 of them. A significant correlation was found at baseline between GS and 18F-MISO TBR, between 18F-MISO TBR and MRI perfusion markers, between GS and 18F-FCH maximum standardized uptake value, between GS and PIRADS score, and between 18F-FCH maximum standardized uptake value and PIRADS score. No difference was found between 18F-MISO-positive and -negative biopsy specimens with respect to tissue biomarkers. The TBR of 18F-MISO diminished significantly after nADT only in high-grade lesions and in regions with a significant uptake at baseline. CONCLUSIONS: PET imaging with 18F-MISO showed variable uptake in PCa, associated with a higher GS, lowering significantly after 3 months of nADT in high-grade lesions. These results suggest the existence of a hypoxic microenvironment in PCa and a reoxygenation effect of nADT.

Hybrid PET-MRI in Alzheimer's Disease Research.

Multiple factors, namely amyloid, tau, inflammation, metabolic, and perfusion changes, contribute to the cascade of neurodegeneration and functional decline occurring in Alzheimer's disease (AD). These molecular and cellular processes and related functional and morphological changes can be visualized in vivo by two imaging modalities, namely positron emission tomography (PET) and magnetic resonance imaging (MRI). These imaging biomarkers are now part of the diagnostic algorithm and of particular interest for patient stratification and targeted drug development.In this field the availability of hybrid PET/MR systems not only offers a comprehensive evaluation in a single imaging session, but also opens new possibilities for the integration of the two imaging information. Here, we cover the clinical protocols and practical details of FDG, amyloid, and tau PET/MR imaging as applied in our institutions.

FDG PET/MR Imaging in Major Neurocognitive Disorders.

PET/MRI tomographs represent the latest development in hybrid molecular imaging, opening new perspectives for clinical and research applications and attracting a large interest among the medical community. This new hybrid modality is expected to play a pivotal role in a number of clinical applications and among these the assessment of neurodegenerative disorders. PET and MRI, acquired separately, are already the imaging biomarkers of choice for a comprehensive assessment of the changes occurring in dementias (major cognitive disorders) as well as in their prodromal phase. In this paper we review the current evidence on the use of integrated PET/MRI scanners to investigate patients with neurodegenerative conditions, and in particular major neurocognitive disorders. The number of studies performed is still limited and shows that the use of PET/MRI gives results overall comparable to PET/CT and MRI acquired independently. We also address the challenges for quantitative aspects in PET/MRI, namely attenuation, partial volume and motion correction and the use of semi-quantitative approaches for FDG PET image analysis in this framework. The recent development of PET tracers for the in vivo differential diagnosis of dementias, able to visualize amyloid and tau deposits, suggests that in the future PET/MRI might represent the investigation of choice for a single session evaluation of morphological, functional and molecular markers.

Scintigraphic Identification of Gastric Tissue in a Mediastinal Mass.

We present a Tc pertechnetate scintigraphy performed in a 64-year-old woman to investigate a mediastinal cystic mass in search of residual gastric mucosa after gastrectomy. She had a history of esophagectomy and gastric pull-up for esophageal cancer. Postoperative leakage necessitated ablation of the gastric pull-up and reconstruction using part of the colon. Oral realimentation resulted in mediastinal pain and brownish discharge within the trachea, raising the suspicion of residual gastric pouch. SPECT/CT demonstrated increased tracer uptake in the median part of the mediastinal cyst, and a biopsy confirmed the presence gastric mucosa.

Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome.

BACKGROUND: Gait impairment is common in parkinsonian syndromes but not specific to striatonigral dysfunction. The relationship between the dopaminergic system and gait parameters is poorly understood. This cross-sectional study aimed to determine if gait measures are related to the striatal dopamine transporters distribution using [(123)I]FP-CIT SPECT in patients with parkinsonian syndromes. MATERIALS AND METHODS: Twenty-four patients with gait impairment and parkinsonian syndromes without Parkinson's disease (mean age: 73.6±8.2years) were included in this study. Gait analysis during single- and dual-task condition (walking and backwards counting) and [(123)I]FP-CIT SPECT were performed within 3months of each other. Patients were visually categorized as having normal (n=14) or abnormal (n=10) [(123)I]FP-CIT SPECT. In addition, a volume-of-interest-based analysis of uptake ratios (caudate and putamen) relative to the occipital cortex and a voxelwise analysis using SPM8 were also performed. RESULTS: Patients with parkinsonian syndromes and abnormal [(123)I]FP-CIT SPECT did not significantly differ in terms of spatiotemporal gait parameters from those with normal [(123)I]FP-CIT SPECT. Moreover, after correction for multiple comparisons, we did not observe any association between regional uptake ratio and spatiotemporal gait parameters for single and dual tasking. Finally, none of these parameters showed a significant association with voxelwise [(123)I]FP-CIT uptake. CONCLUSIONS: Dopaminergic denervation, as measured by [(123)I]FP-CIT SPECT, is not necessary to induce alterations of spatiotemporal gait parameters during single and dual task in patients presenting with atypical parkinsonian syndromes.